Literature DB >> 17975186

Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians.

Amir Qaseem1, Vincenza Snow, Paul Shekelle, Katherine Sherif, Timothy J Wilt, Steven Weinberger, Douglas K Owens.   

Abstract

RECOMMENDATION 1: In patients with respiratory symptoms, particularly dyspnea, spirometry should be performed to diagnose airflow obstruction. Spirometry should not be used to screen for airflow obstruction in asymptomatic individuals. (Grade: strong recommendation, moderate-quality evidence.) RECOMMENDATION 2: Treatment for stable chronic obstructive pulmonary disease (COPD) should be reserved for patients who have respiratory symptoms and FEV1 less than 60% predicted, as documented by spirometry. (Grade: strong recommendation, moderate-quality evidence.) RECOMMENDATION 3: Clinicians should prescribe 1 of the following maintenance monotherapies for symptomatic patients with COPD and FEV1 less than 60% predicted: long-acting inhaled beta-agonists, long-acting inhaled anticholinergics, or inhaled corticosteroids. (Grade: strong recommendation, high-quality evidence.) RECOMMENDATION 4: Clinicians may consider combination inhaled therapies for symptomatic patients with COPD and FEV1 less than 60% predicted. (Grade: weak recommendation, moderate-quality evidence.) RECOMMENDATION 5: Clinicians should prescribe oxygen therapy in patients with COPD and resting hypoxemia (Pao2 < or =55 mm Hg). (Grade: strong recommendation, moderate-quality evidence.) RECOMMENDATION 6: Clinicians should consider prescribing pulmonary rehabilitation in symptomatic individuals with COPD who have an FEV1 less than 50% predicted. (Grade: weak recommendation, moderate-quality evidence.).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975186

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  48 in total

Review 1.  Update in new medications for primary care.

Authors:  Gerald W Smetana; Jane S Sillman
Journal:  J Gen Intern Med       Date:  2008-11-13       Impact factor: 5.128

2.  Respiratory impairment and mortality in older persons: a novel spirometric approach.

Authors:  Carlos A Vaz Fragoso; Thomas M Gill; Gail McAvay; Henry Klar Yaggi; Peter H Van Ness; John Concato
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

3.  Prescription practices for chronic obstructive pulmonary disease: findings from the national ambulatory medical care survey 1999-2010.

Authors:  Earl S Ford; David M Mannino; Wayne H Giles; Anne G Wheaton; Yong Liu; Janet B Croft
Journal:  COPD       Date:  2014-02-25       Impact factor: 2.409

4.  Chronic obstructive pulmonary disease: an overview.

Authors:  John F Devine
Journal:  Am Health Drug Benefits       Date:  2008-09

5.  Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD.

Authors:  Joseph Seaman; Anthony C Leonard; Ralph J Panos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-04-07

Review 6.  Nebulized formoterol: a review of clinical efficacy and safety in COPD.

Authors:  Nicholas J Gross; James F Donohue
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

7.  Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease?

Authors:  R Perez-Padilla; W M Vollmer; J C Vázquez-García; P L Enright; A M B Menezes; A S Buist
Journal:  Int J Tuberc Lung Dis       Date:  2009-03       Impact factor: 2.373

8.  Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy.

Authors:  Kei Nakashima; Masahiro Aoshima; Satoko Ohfuji; Kanzo Suzuki; Masahiro Katsurada; Naoko Katsurada; Masafumi Misawa; Yoshihito Otsuka; Kyoko Kondo; Yoshio Hirota
Journal:  Hum Vaccin Immunother       Date:  2016-11-07       Impact factor: 3.452

Review 9.  Safety, tolerability and risk benefit analysis of tiotropium in COPD.

Authors:  Yuji Oba; Tareq Zaza; Danish M Thameem
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.

Authors:  Andrea Rossi; Sonia Khirani; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.